← Bangkok Dusit Medical Services overview

Bangkok Dusit Medical Services vs Bumrungrad Hospital PCL: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)

Q3 2026
▲2▼2

BDMS Q3 profit hits record as revenue rebounds, but foreign outflows and floods weigh

  • Record Q3 profit and revenue rebound BDMS reported a record quarterly profit near 4.5 billion baht, with August revenue up 9–10% and occupancy recovering to 65% after a weak Q2. Analysts upgraded target prices to 23.50–25.00 baht.

    This is the main positive driver of the stock's performance in Q3.

  • Weak baht and seasonal illness demand A weaker Thai baht boosted international revenue when converted back to baht, while a flu and COVID wave increased patient volumes. The WellEra wellness project also contributed to growth.

    These are key tailwinds that supported revenue and profit growth.

  • Foreign investor selling and high US yields Foreign investors sold 30.5 billion baht of Thai stocks in seven days, driven by Fed rate hikes that pushed US yields to 5.30%. This created downward pressure on BDMS and the broader market.

    This was a major negative force affecting stock price despite strong company results.

  • Floods and high interest rates cap market Flooding in parts of Thailand and elevated interest rates limited overall market gains and investor sentiment, preventing BDMS from fully benefiting from its operational momentum.

    These external risks acted as a counterweight to the positive company-specific news.

September 2026
▲3▼1

BDMS Surges on Record Q3 Profit and Upgraded Targets

  • Record Q3 Profit and Strong August Revenue BDMS is set to report record Q3 profit near 4.5 billion baht, with August revenue up 9-10% year-on-year, the first double-digit growth since early 2024, driven by Thai, insured, and Middle East patients.

    This is the core new financial performance that drove bullish sentiment and target upgrades.

  • Broker Target Upgrades Major brokers including TISCO, Krungsri, KGI, KKPS, Asia Plus, and CGSI raised their price targets to 23.50-25.00 baht, reflecting confidence in BDMS's earnings recovery and growth outlook.

    Broker upgrades directly influence investor sentiment and can drive buying interest.

  • Multiple Tailwinds Support Growth A weak baht, defensive appeal amid high rates, a flu/COVID wave, tighter FDA control of GLP-1 drugs, a cancer vaccine, flood demand, and a growing wellness market (target: 20% of revenue by 2035) are boosting BDMS's prospects.

    These factors collectively enhance demand and position BDMS favorably in the current environment.

  • Foreign Selling and Macro Risks Foreign investors sold 30.5 billion baht in seven days, and Fed rate hikes pushed US yields to 5.30%, while floods and high rates capped the broader market, posing risks to BDMS's stock performance.

    These external pressures could offset positive company-specific news and weigh on the stock.

Latest
▲3

Brokers pile into BDMS as Q3 profit recovery and defensive appeal build

  • Brokers raise BDMS targets on Q3 profit recovery KKPS, Asia Plus, CGSI and Land and Houses all back BDMS, with targets of 23.50-25.00 baht. They say hospital earnings passed their low point in Q2, August revenue grew 9-10% year-on-year, and Q3 profit should recover both year-on-year and quarter-on-quarter.

    Multiple fresh broker upgrades and higher targets are the main force lifting BDMS shares this period.

  • Flu wave and FDA drug rule lift patient demand Asia Plus says influenza cases jumped to 48,100 in mid-September from 21,753 the week before, with COVID-19 also rising, boosting hospital visits. Separately, tighter FDA control of GLP-1 weight-loss drugs pushes users into standard hospitals, where BDMS has a large network.

    These are new, concrete demand drivers that raise patient volumes and revenue per patient.

  • Cancer vaccine and flood demand add new growth angles Asia Plus flags BDMS as a main beneficiary of a Thai-developed personalized cancer vaccine that could cut treatment costs to about 1 million baht, lifting revenue per cancer patient. Asia Plus and InnovestX also name BDMS as a short-term flood beneficiary and a fast-recovery play.

    New technology and event-driven demand stories give investors fresh reasons to buy BDMS.

  • Defensive status helps, but foreign selling and floods weigh The Fed raised rates to 3.75-4.00%, pushing US 10-year yields to 5.30% and driving 30.5 billion baht of foreign selling in seven days. Brokers still name BDMS a defensive, low-volatility pick, but warn floods and high rates could cap the broader market.

    This is the real counterweight: money leaving Thai stocks limits how far BDMS can rise even with good news.

▲4

BDMS Rides Record Q3 Profit Forecasts and Weak-Baht Tailwind

  • Brokers hike targets on record Q3 profit TISCO raised its BDMS target to 24.50 baht and lifted 2026-2028 earnings forecasts by 7-9%. Krungsri and KGI both see a record third-quarter profit near 4.5 billion baht, up sharply from Q2, as revenue growth accelerates to around 9-10%.

    This is the core new reason the stock is moving: analysts now expect a record profit rebound, not just a bottom.

  • August revenue growth hits 10%, first double-digit since 2024 August hospital revenue grew 10% year-on-year, up from 8% in July, the first double-digit growth since early 2024. Thai patients, insured patients and a recovering Middle East segment are all contributing, easing the drag from Cambodia and Middle East unrest seen in Q2.

    It shows the operational recovery is real and broadening, which underpins the higher profit forecasts.

  • Weak baht and Fed hike make BDMS a defensive pick The baht has weakened past 33 per dollar and the Fed raised rates again, pushing bond yields to multi-year highs. Brokers including Pie, KSS and InnovestX name BDMS among value or defensive stocks that benefit from medical tourism and steady domestic revenue.

    It explains the macro force steering new money into BDMS even as the broad market weakens.

  • Wellness push adds long-term growth story KGI notes Thailand's wellness market is worth $42.7 billion and growing 7-10% a year. BDMS aims to lift wellness to 20% of revenue by 2035 from 12% in 2025, with the WellEra project valued at 26.5 billion baht as a long-term driver.

    It gives a structural reason beyond the current profit cycle for why investors are positive on BDMS.

August 2026
▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

Bumrungrad Hospital PCL (BH.BK)

Q3 2026
▲2▼2

Bumrungrad Q3: Strong Profit, Phuket Expansion, But Macro Risks

  • Q2 Profit Beat and Dividend Bumrungrad's Q2 net profit beat expectations at 1.89 billion baht, helped by 7.1% growth in international patient revenue. This led to an Asia Plus upgrade to buy with a 220 baht target and a 4 baht interim dividend.

    This is a key positive event that drove the stock in Q3.

  • Phuket Hospital and Foreign Patient Growth Bumrungrad advanced on its new 4.3 billion baht Phuket hospital and foreign patients reaching 66% of revenue, with Middle East up 18.8%. Expected Q3 profit growth of 10.5% also supported the stock.

    This expansion and growth in foreign patients is a new positive driver.

  • Middle East Tensions and Inflation Fears Middle East tensions pushed Brent above $90, fueling inflation and interest-rate fears that pressured hospital stocks. Foreign outflows and higher US yields also weighed on the stock.

    This macro risk was a negative force during the period.

  • Domestic Weakness and Operational Risks Thai patient revenue fell 2%, and risks remain including competition, staff shortages, floods, and Middle East conflict. These factors could limit future growth.

    This highlights the counterweights to the positive drivers.

September 2026
▲3▼1

BH gains on Phuket hospital, foreign patients, Q3 profit outlook

  • New Phuket hospital adds growth engine BH is building a 4.3 billion baht, 120-bed hospital in Phuket, opening in the third quarter of 2026. This gives the company a second location to serve medical tourists and supports future revenue growth.

    This is a new expansion project not mentioned in earlier reports and a key positive driver.

  • Foreign patient revenue rises, led by Middle East Foreign patients now make up 66% of BH's revenue and are increasing. Middle Eastern visitors rose 18.8% in September, showing strong demand from overseas patients and supporting earnings.

    This is a new update on foreign patient trends and a major positive driver for the stock.

  • Q3 profit expected to grow 10.5% Analysts expect BH's third-quarter core profit to rise 10.5% to 2.088 billion baht. This upbeat earnings outlook, along with new services like a cancer centre and modest price increases, supports the bullish case.

    This is a new earnings forecast for Q3 and a key positive catalyst.

  • Thai patient revenue slips and risks remain Thai patient revenue fell 2%, and brokers warn of foreign outflows, higher US yields, tougher premium competition, staff shortages, floods, and Middle East conflict. These factors could pressure the stock despite the positive outlook.

    This is a new negative development and a fair counterweight to the positive drivers.

Latest
▲3

Brokers turn bullish on BH as Q3 profit set to recover

  • Brokers raise targets, call Q3 the bottom KKPS, CGSI, Maybank and Phillip all name BH a top pick this period, with targets of 200–230 baht. They say hospital profits have passed their low point and will recover in the second half, helped by returning foreign patients. More buy calls can pull money into the stock.

    Multiple new broker upgrades and top-pick calls are the main fresh force behind BH's price.

  • Q3 profit seen up 10.5% on Middle East patients Phillip expects BH's Q3 2026 core profit at 2.088 billion baht, up 10.5% from Q2, with hospital revenue up 8.3%. Middle East visitors to Thailand rose 18.8% in September, lifting international patient revenue. Better margins and the best quarter of the year support the stock.

    This is the first concrete earnings estimate for the quarter and directly explains the profit recovery story.

  • New cancer vaccine and drug rules favour BH Asia Plus says BH is a standout beneficiary of a Thai-developed personalized cancer vaccine, which could cut treatment costs and raise revenue per patient. Tighter FDA rules on GLP-1 weight-loss drugs also push users toward hospitals. Both are medium-term positives, not yet in forecasts.

    These are new technology and regulation catalysts that could add revenue over time.

  • Foreign selling and floods cloud the picture Foreign investors sold 30.6 billion baht of Thai stocks in seven days as US bond yields hit 5.30%, and floods plus Golden Week image risks could cut Q3 GDP. Asia Plus lists BH among defensive healthcare names, but the weak market and Middle East conflict remain risks.

    This is the main counterweight: it explains why BH may not rise smoothly despite the good news.

▲3

BH's Phuket expansion and foreign-patient growth draw fresh buy calls

  • 4.3bn baht Phuket hospital opens as second growth engine BH is spending over 4.3 billion baht on a new Phuket hospital near the airport, first phase 120 beds (expandable to 212), opening in the third quarter of 2026. It adds capacity and taps medical and wellness tourism, giving the company a second revenue source beyond its Bangkok flagship.

    This is the period's biggest new company-specific event and the main reason brokers raised targets.

  • Pi Securities initiates buy, 220 baht target on foreign patients Pi Securities recommends buying BH with a 220 baht fair value, 12.5% above the 195.50 baht price, expecting profit growth of 3.6% in 2026 and 3.2% in 2027. Foreign patients are 66% of revenue and rising, led by Myanmar, Middle East and US visitors, while Thai patient revenue slipped 2%.

    A fresh analyst call with detailed numbers is a direct new driver of how investors value the shares.

  • Weak baht and rising oil put BH in broker value lists Asia Plus, Pie Securities and Bualuang all name BH among top picks, citing the weak baht (33.16-33.38 per dollar) attracting medical tourists and strong third-quarter profit growth. The same brokers warn of foreign outflows, higher US yields and a possible Fed rate hike, which caps how much the stock can gain.

    Shows the supportive macro backdrop and the offsetting risk that shapes BH's price this period.

  • Cancer centre and price rises support long-term value, competition is the risk BH is building a six-storey cancer centre on Sukhumvit Soi 1, expanding exam rooms from 10 to 23 and adding 59 beds by end-2027, and can raise treatment prices about 5% a year, above inflation. Pi flags tougher premium-healthcare competition, reliance on foreign patients and medical staff shortages as key risks.

    Gives the fair counterweight: long-term growth levers exist but competition and dependence on foreign patients could limit gains.

August 2026
▲3▼1

BH's Q2 beat and buy upgrade offset by oil and inflation worries

  • Q2 profit beat and broker upgrade BH reported Q2 2026 net profit of 1.89 billion baht, up 1.7% from a year earlier, driven by a 7.1% rise in international patient revenue. Shares rose 3.95% to 197.50 baht, and Asia Plus upgraded the stock to buy with a 220 baht target, citing a stronger second half.

    This is the main new positive event that directly moved BH's price and improved its earnings outlook.

  • Interim dividend of 4 baht announced BH declared an interim dividend of 4.00 baht per share, with the ex-dividend date on August 28. This returns cash to shareholders and can attract income-focused investors, supporting the stock price.

    The dividend is a new concrete capital return that affects investor demand for the stock.

  • Oil surge and inflation fears pressure hospitals Brent crude jumped above $90 on Middle East tensions, raising concerns about inflation and interest rates. Hospitals, including BH, were sold off as investors worried that higher costs and weaker consumer spending could reduce demand for elective medical tourism.

    This is a new external risk that directly pushed BH's price down and remains a headwind.

  • BH seen as top pick amid competition CGSI said new premium clinics in public hospitals will pressure mid-tier private hospitals, but named BH a top pick because of its focus on medical tourism and high share of foreign patients. This positions BH to gain market share as weaker rivals struggle.

    This new analyst view highlights BH's competitive advantage and supports its long-term demand outlook.

▲3▼1

BH's Q2 beat and buy upgrade offset by oil and inflation worries

  • Q2 profit beat and broker upgrade BH reported Q2 2026 net profit of 1.89 billion baht, up 1.7% from a year earlier, driven by a 7.1% rise in international patient revenue. Shares rose 3.95% to 197.50 baht, and Asia Plus upgraded the stock to buy with a 220 baht target, citing a stronger second half.

    This is the main new positive event that directly moved BH's price and improved its earnings outlook.

  • Interim dividend of 4 baht announced BH declared an interim dividend of 4.00 baht per share, with the ex-dividend date on August 28. This returns cash to shareholders and can attract income-focused investors, supporting the stock price.

    The dividend is a new concrete capital return that affects investor demand for the stock.

  • Oil surge and inflation fears pressure hospitals Brent crude jumped above $90 on Middle East tensions, raising concerns about inflation and interest rates. Hospitals, including BH, were sold off as investors worried that higher costs and weaker consumer spending could reduce demand for elective medical tourism.

    This is a new external risk that directly pushed BH's price down and remains a headwind.

  • BH seen as top pick amid competition CGSI said new premium clinics in public hospitals will pressure mid-tier private hospitals, but named BH a top pick because of its focus on medical tourism and high share of foreign patients. This positions BH to gain market share as weaker rivals struggle.

    This new analyst view highlights BH's competitive advantage and supports its long-term demand outlook.

© 2026 MarketIVWhy